Published in J Biol Chem on March 15, 1993
Internalization and sorting of a fluorescent analogue of glucosylceramide to the Golgi apparatus of human skin fibroblasts: utilization of endocytic and nonendocytic transport mechanisms. J Cell Biol (1994) 2.01
Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Natl Acad Sci U S A (1999) 1.95
Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL. J Cell Biol (1995) 1.86
Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc Natl Acad Sci U S A (2002) 1.54
Distinct mechanisms of clathrin-independent endocytosis have unique sphingolipid requirements. Mol Biol Cell (2006) 1.49
Genetic evidence for ATP-dependent endoplasmic reticulum-to-Golgi apparatus trafficking of ceramide for sphingomyelin synthesis in Chinese hamster ovary cells. J Cell Biol (1999) 1.37
Suppressor gene analysis reveals an essential role for sphingolipids in transport of glycosylphosphatidylinositol-anchored proteins in Saccharomyces cerevisiae. J Bacteriol (1997) 1.35
Imaging mass spectrometry technology and application on ganglioside study; visualization of age-dependent accumulation of C20-ganglioside molecular species in the mouse hippocampus. PLoS One (2008) 1.31
Biosynthesis and degradation of mammalian glycosphingolipids. Philos Trans R Soc Lond B Biol Sci (2003) 1.29
Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance. J Biol Chem (2008) 1.28
Physical and functional association of glycolipid N-acetyl-galactosaminyl and galactosyl transferases in the Golgi apparatus. Proc Natl Acad Sci U S A (2001) 1.10
Topology of sphingolipid galactosyltransferases in ER and Golgi: transbilayer movement of monohexosyl sphingolipids is required for higher glycosphingolipid biosynthesis. J Cell Biol (1996) 1.05
The mitochondria-associated endoplasmic-reticulum subcompartment (MAM fraction) of rat liver contains highly active sphingolipid-specific glycosyltransferases. Biochem J (2003) 1.02
Cholesterol depletion reduces Helicobacter pylori CagA translocation and CagA-induced responses in AGS cells. Infect Immun (2008) 1.01
Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci (2003) 1.00
Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells. Breast Cancer Res (2008) 0.98
Cerebellar neurons lacking complex gangliosides degenerate in the presence of depolarizing levels of potassium. Proc Natl Acad Sci U S A (2001) 0.98
Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide. Infect Immun (2010) 0.96
Intervention of carbohydrate recognition by proteins and nucleic acids. Proc Natl Acad Sci U S A (1996) 0.96
GA2/GM2/GD2 synthase localizes to the trans-golgi network of CHO-K1 cells. Biochem J (1999) 0.95
Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders. Int J Mol Sci (2016) 0.94
Developmental and tissue-specific expression of prosaposin mRNA in murine tissues. Am J Pathol (1994) 0.94
Glucosamine induces cell-cycle arrest and hypertrophy of mesangial cells: implication of gangliosides. Biochem J (2005) 0.93
Decrease of glomerular disialogangliosides in puromycin nephrosis of the rat. Am J Pathol (1996) 0.92
Biosynthesis and functions of gangliosides: recent advances. Glycoconj J (1998) 0.89
Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles. J Lipid Res (2014) 0.89
The roles of glycosphingolipids in the proliferation and neural differentiation of mouse embryonic stem cells. Exp Mol Med (2009) 0.89
Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies. Front Oncol (2014) 0.88
Single cell ganglioside catabolism in primary cerebellar neurons and glia. Neurochem Res (2012) 0.86
Alterations in neuroblastoma ganglioside synthesis by induction of GD1b synthase by retinoic acid. Br J Cancer (2004) 0.86
Glycosphingolipid degradation and animal models of GM2-gangliosidoses. J Inherit Metab Dis (1998) 0.85
Expression cloning of a CMP-NeuAc:NeuAc alpha 2-3Gal beta 1-4Glc beta 1-1'Cer alpha 2,8-sialyltransferase (GD3 synthase) from human melanoma cells. Proc Natl Acad Sci U S A (1994) 0.84
Modulation of growth factor signaling by gangliosides: positive or negative? Methods Enzymol (2006) 0.84
Synthesis of biologically active N- and O-linked glycans with multisialylated poly-N-acetyllactosamine extensions using P. damsela α2-6 sialyltransferase. J Am Chem Soc (2013) 0.84
Inactivation of ceramide synthase 6 in mice results in an altered sphingolipid metabolism and behavioral abnormalities. J Biol Chem (2013) 0.84
Interruption of glycosphingolipid synthesis enhances osteoarthritis development in mice. Arthritis Rheum (2012) 0.82
Polysialic acid engineering: synthesis of polysialylated neoglycosphingolipids by using the polysialyltransferase from neuroinvasive Escherichia coli K1. Proc Natl Acad Sci U S A (1994) 0.82
Low complex ganglioside expression characterizes human neuroblastoma cell lines. Cancer Lett (2005) 0.80
Quantitative transcriptomic profiling of branching in a glycosphingolipid biosynthetic pathway. J Biol Chem (2011) 0.80
My journey into the world of sphingolipids and sphingolipidoses. Proc Jpn Acad Ser B Phys Biol Sci (2012) 0.79
Stimulation of GLUT4 (glucose transporter isoform 4) storage vesicle formation by sphingolipid depletion. Biochem J (2010) 0.79
Induction of GM1a/GD1b synthase triggers complex ganglioside expression and alters neuroblastoma cell behavior; a new tumor cell model of ganglioside function. Glycoconj J (2011) 0.78
Sialic Acid Is Required for Neuronal Inhibition by Soluble MAG but not for Membrane Bound MAG. Front Mol Neurosci (2016) 0.75
Dynamics of glycolipid domains in the plasma membrane of living cultured neurons, following protein kinase C activation: a study performed by excimer-formation imaging. Biochem J (1999) 0.75
Ganglioside-magnetosome complex formation enhances uptake of gangliosides by cells. Int J Nanomedicine (2015) 0.75
Identification and Functional Characterization of ST3GAL5 and ST8SIA1 Variants in Patients with Thyroid-Associated Ophthalmopathy. Yonsei Med J (2017) 0.75
Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat Genet (1995) 2.66
Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet (1995) 2.64
CD95 signaling via ceramide-rich membrane rafts. J Biol Chem (2001) 2.48
Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci (1984) 2.23
Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet (1992) 2.12
Enzyme alterations and lipid storage in three variants of Tay-Sachs disease. J Neurochem (1971) 2.11
A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A (1999) 2.05
The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression. Genomics (1999) 2.04
AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. Proc Natl Acad Sci U S A (1978) 2.02
A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J Clin Invest (1999) 1.96
Deficient hexozaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs. Life Sci (1968) 1.95
Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. J Biol Chem (1991) 1.89
Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta (2000) 1.77
Subcellular localization and membrane topology of serine palmitoyltransferase, 3-dehydrosphinganine reductase, and sphinganine N-acyltransferase in mouse liver. J Biol Chem (1992) 1.76
Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet (1996) 1.70
Evidence for two different active sites on human beta-hexosaminidase A. Interaction of GM2 activator protein with beta-hexosaminidase A. J Biol Chem (1985) 1.66
Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures. J Biol Chem (2000) 1.64
Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nat Genet (1996) 1.63
Isolation of cDNA clones encoding human acid sphingomyelinase: occurrence of alternatively processed transcripts. EMBO J (1989) 1.55
Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J Clin Invest (1998) 1.49
Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease. J Biol Chem (1996) 1.49
Lysosomal enzyme precursors in human fibroblasts. Activation of cathepsin D precursor in vitro and activity of beta-hexosaminidase A precursor towards ganglioside GM2. Eur J Biochem (1982) 1.48
Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell (1997) 1.47
Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim Biophys Acta (1992) 1.46
The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler (1994) 1.46
[Enrichment and characterization of 2 forms of human N-acetyl-beta-D-hexosaminidase]. Hoppe Seylers Z Physiol Chem (1971) 1.45
GM2-gangliosidosis B1 variant: analysis of beta-hexosaminidase alpha gene abnormalities in seven patients. Am J Hum Genet (1990) 1.43
Characterization of ceramide synthesis. A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide. J Biol Chem (1997) 1.37
Ganglioside GM2 N-acetyl-beta-D-galactosaminidase activity in cultured fibroblasts of late-infantile and adult GM2 gangliosidosis patients and of healthy probands with low hexosaminidase level. Am J Hum Genet (1983) 1.36
Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study. J Inherit Metab Dis (2005) 1.36
Metabolism and intracellular transport of glycosphingolipids. Biochemistry (1990) 1.34
Deficient hexosaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs. Pathol Eur (1968) 1.34
Sphingolipid activator proteins are required for epidermal permeability barrier formation. J Biol Chem (1999) 1.32
Stimulation of acid sphingomyelinase activity by lysosomal lipids and sphingolipid activator proteins. Biol Chem (2001) 1.32
Cerebroside sulfatase activator deficiency induced metachromatic leukodystrophy. Am J Hum Genet (1981) 1.29
Acid sphingomyelinase from human urine: purification and characterization. Biochim Biophys Acta (1987) 1.26
Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis (2004) 1.26
Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEBS Lett (1991) 1.26
Cellular uptake of saposin (SAP) precursor and lysosomal delivery by the low density lipoprotein receptor-related protein (LRP). EMBO J (1998) 1.25
Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J Biol Chem (1993) 1.25
A mutation in the gene of a glycolipid-binding protein (GM2 activator) that causes GM2-gangliosidosis variant AB. FEBS Lett (1991) 1.24
Lysogangliosides: synthesis and use in preparing labeled gangliosides. Methods Enzymol (1987) 1.24
Purification and characterization of an activator protein for the degradation of glycolipids GM2 and GA2 by hexosaminidase A. Hoppe Seylers Z Physiol Chem (1979) 1.24
Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem (1995) 1.23
Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure. Proc Natl Acad Sci U S A (1998) 1.23
Specificity of human liver hexosaminidases A and B against glycosphingolipids GM2 and GA2. Purification of the enzymes by affinity chromatography employing specific elution. Hoppe Seylers Z Physiol Chem (1977) 1.20
Biochemistry and genetics of gangliosidoses. Hum Genet (1979) 1.20
Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators. J Biol Chem (1998) 1.20
Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med (2000) 1.19
Incorporation and metabolism of ganglioside GM2 in skin fibroblasts from normal and GM2 gangliosidosis subjects. Eur J Biochem (1985) 1.16
Complexing of glycolipids and their transfer between membranes by the activator protein for degradation of lysosomal ganglioside GM2. Eur J Biochem (1982) 1.16
Incorporation of ganglioside analogues into fibroblast cell membranes. A spin-label study. Biochemistry (1983) 1.15
Cloning and characterization of the full-length cDNA and genomic sequences encoding murine acid ceramidase. Genomics (1998) 1.15
Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis (2003) 1.15
Occurrence of two molecular forms of human acid sphingomyelinase. Biochem J (1994) 1.15
Variant of GM2-gangliosidosis with hexosaminidase A having a severely changed substrate specificity. EMBO J (1983) 1.13
Characterization of full-length cDNAs and the gene coding for the human GM2 activator protein. FEBS Lett (1991) 1.13
[Resolution of mammalian N-acetyl-beta-D-hexosaminidase into multiple forms by electrofocussing]. Hoppe Seylers Z Physiol Chem (1968) 1.12
Structure of full-length cDNA coding for sulfatide activator, a Co-beta-glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator. J Biochem (1989) 1.12
Sulfatide activator protein. Alternative splicing that generates three mRNAs and a newly found mutation responsible for a clinical disease. J Biol Chem (1991) 1.10
The precursor of sulfatide activator protein is processed to three different proteins. Biol Chem Hoppe Seyler (1988) 1.09
The human GM2 activator protein. A substrate specific cofactor of beta-hexosaminidase A. J Biol Chem (1991) 1.08
Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease type B patients from northern Africa. Hum Genet (1993) 1.08
Biosynthesis, processing, and targeting of sphingolipid activator protein (SAP )precursor in cultured human fibroblasts. Mannose 6-phosphate receptor-independent endocytosis of SAP precursor. J Biol Chem (1996) 1.07
Uncoupling of ganglioside biosynthesis by Brefeldin A. Eur J Cell Biol (1990) 1.06
Human acid ceramidase: processing, glycosylation, and lysosomal targeting. J Biol Chem (2001) 1.06
Molecular genetics of GM2-gangliosidosis AB variant: a novel mutation and expression in BHK cells. Hum Genet (1993) 1.05
Modulation of ganglioside biosynthesis in primary cultured neurons. J Neurochem (1989) 1.05
Over-expression of a functionally active human GM2-activator protein in Escherichia coli. Biochem J (1993) 1.04
Sphingolipid biosynthesis in cultured neurons. Down-regulation of serine palmitoyltransferase by sphingoid bases. Eur J Biochem (1991) 1.03
The biochemical basis of gangliosidoses. Neuropediatrics (1984) 1.03
[A disorder of ganglioside metabolism with storage of ceramide lactoside, monosialo ceramide lactoside and Tay-Sachs ganglioside in the brain]. J Neurochem (1966) 1.03
Biosynthesis of sphingolipids: dihydroceramide and not sphinganine is desaturated by cultured cells. Biochem Biophys Res Commun (1992) 1.03
Molecular analysis of a GM2-activator deficiency in two patients with GM2-gangliosidosis AB variant. Am J Hum Genet (1996) 1.03
Molecular basis of acid sphingomyelinase deficiency in a patient with Niemann-Pick disease type A. Biochem Biophys Res Commun (1991) 1.03
Biochemical basis of late-onset neurolipidoses. Dev Neurosci (1991) 1.03
Fas/CD95/Apo-I activates the acidic sphingomyelinase via caspases. Cell Death Differ (1998) 1.02
Interfacial regulation of acid ceramidase activity. Stimulation of ceramide degradation by lysosomal lipids and sphingolipid activator proteins. J Biol Chem (2000) 1.01
Comparative dynamics and location of chain spin-labelled sphingomyelin and phosphatidylcholine in dimyristoyl phosphatidylcholine membranes studied by EPR spectroscopy. Biochim Biophys Acta (2000) 1.01
Sphingolipid activator proteins: proteins with complex functions in lipid degradation and skin biogenesis. Glycobiology (2001) 1.01
Tunicamycin inhibits ganglioside biosynthesis in rat liver Golgi apparatus by blocking sugar nucleotide transport across the membrane vesicles. Proc Natl Acad Sci U S A (1983) 1.01
Recent advances in the biochemistry of sphingolipidoses. Brain Pathol (1998) 1.00
Genomic organization of the gene coding for TIRC7, a novel membrane protein essential for T cell activation. Genomics (1999) 0.99
Functional characterization of the N-glycosylation sites of human acid sphingomyelinase by site-directed mutagenesis. Eur J Biochem (1997) 0.99
Processing of human acid sphingomyelinase in normal and I-cell fibroblasts. J Biol Chem (1994) 0.98
Glycosphingolipid specificity of the human sulfatide activator protein. Eur J Biochem (1991) 0.98
Immunochemical and biochemical investigation of hexosaminidase S. Am J Hum Genet (1977) 0.98
Biosynthesis, processing, and intracellular transport of GM2 activator protein in human epidermal keratinocytes. The lysosomal targeting of the GM2 activator is independent of a mannose-6-phosphate signal. J Biol Chem (1997) 0.98
Mapping of the gene coding for the human GM2 activator protein to chromosome 5. Ann Hum Genet (1985) 0.98
Purification, biochemical and immunological characterisation of hexosaminidase A from variant AB of infantile GM2 gangliosidosis. Eur J Biochem (1978) 0.97
The complete amino-acid sequences of human ganglioside GM2 activator protein and cerebroside sulfate activator protein. Eur J Biochem (1990) 0.97
Degradation of membrane-bound ganglioside GM2 by beta -hexosaminidase A. Stimulation by GM2 activator protein and lysosomal lipids. J Biol Chem (2001) 0.97
Accumulation of protein-bound epidermal glucosylceramides in beta-glucocerebrosidase deficient type 2 Gaucher mice. FEBS Lett (1999) 0.97
Lipid-protein interactions and effect of local anesthetics in acetylcholine receptor-rich membranes from Torpedo marmorata electric organ. Biochemistry (2003) 0.97
Isolation of a cDNA encoding the human GM2 activator protein. FEBS Lett (1989) 0.97
Degradation of membrane-bound ganglioside GM1. Stimulation by bis(monoacylglycero)phosphate and the activator proteins SAP-B and GM2-AP. J Biol Chem (2000) 0.96
Activating proteins for ganglioside GM2 degradation by beta-hexosaminidase isoenzymes in tissue extracts from different species. Hoppe Seylers Z Physiol Chem (1983) 0.96
Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment. Proc Natl Acad Sci U S A (1997) 0.96
Both GA2, GM2, and GD2 synthases and GM1b, GD1a, and GT1b synthases are single enzymes in Golgi vesicles from rat liver. Proc Natl Acad Sci U S A (1988) 0.95
Analysis of a splice-site mutation in the sap-precursor gene of a patient with metachromatic leukodystrophy. Am J Hum Genet (1996) 0.94